Webinar
Hatch-Waxman 2025 Year in Review
In 2025, the Hatch-Waxman Act remained a cornerstone of the U.S. pharmaceutical industry, shaping the interplay between brand-name manufacturers and generic competitors. Originally designed to balance innovation with access to affordable drugs, this pivotal legislation continued to shape boardroom discussions, regulatory developments, and courtroom disputes.
Whether you are in-house counsel, a pharmaceutical industry leader, or simply curious about how patents affect healthcare, please join Principals Christina Brown-Marshall and Megan Chacon on January 15, 2026, for valuable insights into:
- Key trends in the pharmaceutical industry
- Legal developments affecting branded and generic drugmakers
- What’s coming up in 2026